Quarterly ResultMay 12, 2026, 04:06 PM
Molecular Partners Q1 Net Loss CHF 13.1M; Clinical Studies Initiated
AI Summary
Molecular Partners reported its Q1 2026 financial results, showing a net loss of CHF 13.14 million, an improvement from the prior year. The company initiated two clinical studies for MP0712 and MP0317, and presented positive preclinical data for MP0632. Molecular Partners maintains a strong financial position with CHF 79 million in cash and short-term deposits, providing a runway until late 2027.
Key Highlights
- Cash and short-term time deposits were CHF 79 million (approx. $100 million) as of March 31, 2026.
- Cash runway is projected to last until late 2027, supporting an expanding pipeline.
- Reported a net loss of CHF 13.14 million for Q1 2026, an improvement from CHF 16.77 million loss in Q1 2025.
- Research and development expenses decreased to CHF 9.45 million in Q1 2026 from CHF 11.92 million in Q1 2025.
- Phase 1/2a trial for lead Radio-DARPin MP0712 (targeting DLL3) has been initiated, with initial data expected in 2026.
- An investigator-initiated Phase 2 study of MP0317 (CD40 agonist) for advanced cholangiocarcinoma has started.
- Preclinical data for Switch-DARPin MP0632, a logic-gated T-cell engager, showed tumor regression.
- Entered a non-exclusive development agreement with Eckert & Ziegler for 225Ac isotopes for Radio-DARPins.